跳至主要内容
临床试验/ISRCTN92101486
ISRCTN92101486已完成不适用

Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a prospective, randomised and controlled pilot study

Solvay Pharmaceuticals GmbH (Germany)0 个研究点目标入组 70 人开始时间: 2006年12月13日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • To be included in the trial, patients had to present IBD. The majority of patients enrolled in this study were hospitalised because of symptoms of active disease and in most of them the clinical activity was confirmed by elevated Clinical Activity Index (CAI) scores in UC or elevated Crohn?s Disease Activity Index (CDAI) scores. The diagnosis of IBD was confirmed by classical clinical and endoscopic means according to the German and Austrian guidelines for UC and CD.

排除标准

  • 1. Surgery during study period
  • 2. Other diseases than IBD

研究者

发起方
Solvay Pharmaceuticals GmbH (Germany)

相似试验

Effect of oral lactulose on clinical and... | 临床试验